Parallel Advisors’s Bicycle Therapeutics BCYC Stock Holding History

Parallel Advisors’s Portfolio BCYC Stock Details BCYC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-5	Closed	-$106	–	3371
2023 Q1	$106	Hold	5	–	–	﹤0.01%	3332
2022 Q4	$148	Hold	5	–	–	﹤0.01%	3226
2022 Q3	$0	Hold	5	–	–	﹤0.01%	3145
2022 Q2	$0	Hold	5	–	–	﹤0.01%	3001
2022 Q1	$0	Hold	5	–	–	﹤0.01%	2973
2021 Q4	$0	Buy	+5	New	+$276	﹤0.01%	3085

Other funds holding BCYC

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

JFG

Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

TCM

Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Parallel Advisors's BCYC Position: Q2 2023 in Review

Parallel Advisors sold out of Bicycle Therapeutics (BCYC) in Q2 2023, closing a stake of 5 shares — an estimated $106 sold.

Parallel Advisors first reported a position in BCYC in Q4 2021 and held it in 6 quarters. The position peaked at $148 in Q4 2022. 85 funds tracked by Wall St. Rank hold BCYC as of Q2 2023.

Parallel Advisors reported no remaining Bicycle Therapeutics position as of Q2 2023 after selling out during the quarter.
Parallel Advisors sold 5 Bicycle Therapeutics shares in Q2 2023, an estimated $106.
Parallel Advisors first reported a position in Bicycle Therapeutics in Q4 2021 and held it in 6 quarters.
Parallel Advisors's Bicycle Therapeutics position peaked at $148 in Q4 2022.
85 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q2 2023.

Based on Parallel Advisors's 13F filing for Q2 2023, filed 4 Aug 2023.